Search Within

Matthew J Matasar

Formats
  1. Meeting Abstract (192)
  2. Journal Article (86)
  3. Book Section (4)
  4. Review (3)
  5. Correspondence (2)
  6. Editorial (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Lymphoma (293)
  5. Survivorship Research (293)
  6. Population Sciences Research Program (113)

More Groups

People
  1. Andrew Zelenetz (118)
  2. David Straus (104)
  3. Ariela Noy (101)
  4. Paul Hamlin (100)
  5. Steven Horwitz (98)
  6. Alison Moskowitz (96)

More People

Years
  1. 2024 (9)
  2. 2023 (12)
  3. 2022 (43)
  4. 2021 (43)
  5. 2020 (23)
  6. 2019 (34)

More Years

Publications
  1. Blood (110)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (22)
  4. Biology of Blood and Marrow Transplantation (11)
  5. Clinical Lymphoma, Myeloma and Leukemia (11)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (120)
  2. American Society of Clinical Oncology (37)
  3. Elsevier Inc. (29)
  4. Wiley Blackwell (26)
  5. Oxford University Press (13)
  6. John Wiley & Sons (10)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Biomarker assessment of PTEN protein expression and gene expression profiling (GEP) in a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Chaturvedi, S.; Schulz, A.; Soler, L. M.; Childs, B. H.; Matasar, M.; Zinzani, P. L.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Cost-effectiveness of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
    Meeting Abstract

    Matasar, M.; Masaquel, A.; Rodrigo, H.; Launonen, A.; Ng, C.; Wang, R.; Fox, D.; Hossain, F.; Li, J.; Roth, J. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A SEER-Medicare analysis of the cost of disease progression after frontline R-CHOP in diffuse large B-cell lymphoma
    Meeting Abstract

    Burke, J. M.; Wang, R.; Hossain, F.; Li, J.; Masaquel, A.; Qiheng, S.; Matasar, M.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Flowers, C.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Closing the gap: Implementation of a novel interactive virtual tumor board to improve expert knowledge sharing in malignant hematology
    Meeting Abstract

    Ciuro, J.; Henry, E.; Housri, N.; Banerjee, R.; Brem, E. A.; Brooks, T.; Derman, B. A.; Hill, B. T.; Hofmeister, C. C.; Lunning, M. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Vitalize trial: A phase 2b, open-label, multicenter, randomized parallel-group, two-stage, study of the novel immunotherapeutic, maveropepimut-S, and pembrolizumab with and without intermittent low-dose cyclophosphamide, in subjects with relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Matasar, M. J.; Lee, E.; Leitch, S.; Solh, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J.
    Blood (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Final results of a phase Ib/II randomized study and single-arm extension (Ext) study
    Meeting Abstract

    Sehn, L. H.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A. K.; Özcan, M.; Safar, V.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save